HC Wainwright Reaffirms Buy Rating for Kura Oncology (NASDAQ:KURA)

Kura Oncology (NASDAQ:KURA)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They currently have a $32.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 72.32% from the stock’s current price.

Other equities analysts also recently issued research reports about the company. Lifesci Capital raised Kura Oncology to a “strong-buy” rating in a research report on Tuesday, October 22nd. UBS Group began coverage on Kura Oncology in a research report on Thursday, October 24th. They set a “buy” rating and a $27.00 price target for the company. Stifel Nicolaus downgraded Kura Oncology from a “buy” rating to a “hold” rating and dropped their price target for the stock from $26.00 to $19.00 in a research report on Monday, October 14th. JMP Securities reaffirmed a “market outperform” rating and issued a $32.00 price objective on shares of Kura Oncology in a research report on Monday, August 12th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $37.00 price objective on shares of Kura Oncology in a research report on Monday, November 4th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $28.83.

Kura Oncology Stock Performance

Kura Oncology stock opened at $18.57 on Wednesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The stock has a fifty day moving average of $18.67 and a two-hundred day moving average of $19.99. The company has a market capitalization of $1.44 billion, a price-to-earnings ratio of -7.87 and a beta of 0.86. Kura Oncology has a fifty-two week low of $8.17 and a fifty-two week high of $24.17.

Institutional Investors Weigh In On Kura Oncology

A number of institutional investors have recently added to or reduced their stakes in the company. nVerses Capital LLC purchased a new stake in Kura Oncology during the third quarter valued at about $25,000. ProShare Advisors LLC lifted its stake in shares of Kura Oncology by 9.7% during the first quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock worth $384,000 after purchasing an additional 1,588 shares in the last quarter. Aaron Wealth Advisors LLC lifted its stake in shares of Kura Oncology by 2.4% during the second quarter. Aaron Wealth Advisors LLC now owns 70,148 shares of the company’s stock worth $1,444,000 after purchasing an additional 1,673 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Kura Oncology by 5.4% during the second quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock worth $793,000 after purchasing an additional 1,976 shares in the last quarter. Finally, Hsbc Holdings PLC lifted its stake in shares of Kura Oncology by 13.4% during the second quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock worth $374,000 after purchasing an additional 2,167 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.